Still, we propose that patients with p53-proficient tumors might be treated with a non-genotoxic p53 activator rather than a CDK4/6 inhibitor for the extra benefit of hyperactivating the powerful tumor-suppressive p53 programs (Fig. 2F). The gene discussed is CDK4; the disease is neoplasm.